title: Does FDG PET-assisted management of patients with left ventricular dysfunction improve quality of life? A substudy of the PARR-2 trial.
abstract: BACKGROUND
  Patients with left ventricular dysfunction whose management is directed by F-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging may have a quality of life (QOL) benefit over standard care.
  
  
  METHODS
  Among 430 patients randomized in the PET and Recovery Following Revascularization (PARR)-2 trial to FDG PET-assisted management vs standard, QOL scores were obtained using the European Quality of Life-5 Dimensions (EQ-5D) in 427 patients at baseline (FDG PET n = 216; standard n = 211) and 355 patients at 12-month follow-up (FDG PET n = 184; standard n = 171). EQ-5D scores between FDG PET and standard arms were compared using mixed model repeated measures (MMRM). Subgroup analysis compared EQ-5D scores between patients in FDG PET who adhered to PET recommendations (Adherence) vs standard using MMRM. Interaction of revascularization with management was assessed using a general linear model.
  
  
  RESULTS
  A trend toward higher EQ-5D scores in FDG PET was observed (P = 0.056). Subgroup analysis showed a significant difference favouring adherence (P = 0.04). Higher QOL at 6 months for FDG PET (P = 0.02) and Adherence (P = 0.02) were observed. For revascularization, an interaction with management (FDG PET vs standard) for QOL was observed (6 months: P = 0.01; 12 months: P = 0.1); Adherence (6 months: P = 0.01; 12 months: P = 0.1).
  
  
  CONCLUSIONS
  FDG PET-directed management improves QOL, at least in the short-term and with adherence to recommendations. This may relate to revascularization, and may indicate better treatment selection using FDG PET.
authors.affiliation: Molecular Function and Imaging Program, The National Cardiac PET Centre, Division of Cardiology, University of Ottawa Heart Institute and the University of Ottawa, Ottawa, Ontario, Canada.
authors.forename: Tushar
authors.initials: T
authors.lastname: Shukla
authors.forename: Graham
authors.initials: G
authors.lastname: Nichol
authors.forename: George
authors.initials: G
authors.lastname: Wells
authors.forename: Robert A
authors.initials: RA
authors.lastname: deKemp
authors.forename: Ross A
authors.initials: RA
authors.lastname: Davies
authors.forename: Haissam
authors.initials: H
authors.lastname: Haddad
authors.forename: Lloyd
authors.initials: L
authors.lastname: Duchesne
authors.forename: Michael
authors.initials: M
authors.lastname: Freeman
authors.forename: Karen
authors.initials: K
authors.lastname: Gulenchyn
authors.forename: Normand
authors.initials: N
authors.lastname: Racine
authors.forename: Dennis
authors.initials: D
authors.lastname: Humen
authors.forename: Francois
authors.initials: F
authors.lastname: Benard
authors.forename: Terrence D
authors.initials: TD
authors.lastname: Ruddy
authors.forename: Benjamin J
authors.initials: BJ
authors.lastname: Chow
authors.forename: Jean
authors.initials: J
authors.lastname: DaSilva
authors.forename: Linda
authors.initials: L
authors.lastname: Garrard
authors.forename: Ann
authors.initials: A
authors.lastname: Guo
authors.forename: Li
authors.initials: L
authors.lastname: Chen
authors.forename: Rob S B
authors.initials: RS
authors.lastname: Beanlands
mesh_terms: D005260:Female; D019788:Fluorodeoxyglucose F18; D005500:Follow-Up Studies; D019983:Guideline Adherence; D006801:Humans; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography / Q000379:methods* / Q000592:standards; D011788:Quality of Life; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D011795:Surveys and Questionnaires; D018487:Ventricular Dysfunction, Left / Q000000981:diagnostic imaging* / Q000503:physiopathology / Q000523:psychology; D016277:Ventricular Function, Left
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18